Knowledge Library

TiCARos Therapeutics Case Study – Accelerating the development of advanced therapies from discovery to biomanufacture

TiCARos Therapeutics has leveraged the expertise of their team of immunologists from Seoul National University, College of Medicine to develop a promising pipeline of nextgeneration immunotherapies for intractable haematologic malignancies and advanced solid tumours. TiCARos’ mission is to create medication based on science. TiCARos was founded by two leading T cell immunologists, who have built …Read More >

Resource Type: Case Study
Resource Topic: Clinical & Commercial Manufacturing

VIEW

WuXi Advanced Therapies Testing Facility & Virtual Tour

 New state-of-the-art advanced therapies testing laboratories provide additional capacity for the growing cell and gene therapy industry. WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, has opened its advanced therapies testing facility at 400 Rouse Boulevard in Philadelphia’s Navy Yard. The new facility, which includes 140,000 square feet laboratories, will …Read More >

Resource Type: Video
Resource Topic: Advanced Testing

VIEW

Improve and Innovate – Next Generation AAV Manufacturing Strategies

Adeno-associated virus (AAV) is often the vector of choice for gene therapies; in fact, AAV represents around 37% of the current advanced therapies market. And when it comes to manufacturing AAV for in vivo gene therapies, developers must pursue triplicate goals of quality, quantity, and speed. At OXGENE and WuXi ATU, our ambition is to …Read More >

Resource Type: Webinar
Resource Topic: Clinical & Commercial Manufacturing

VIEW

TESSA Technology: A Plasmid-Free, Scalable System to Transform AAV Manufacture

The majority of adeno-associated viral (AAV) vector produced globally is manufactured using triple transfection. But plasmid-based AAV manufacture has drawbacks – the need to transfect cells results in a process which cannot be truly scalable, and yield and particle infectivity could be improved upon. Tetracycline Enabled Self Silencing Adenovirus (TESSA) technology utilizes adenovirus to manufacture …Read More >

Resource Type: Webinar
Resource Topic: Clinical & Commercial Manufacturing

VIEW

Rethinking AAV Manufacture “From the Ground Up”

Adenoassociated virus (AAV) is a popular choice of viral vector for new gene therapies, but manufacturing systems have not kept pace with biological advances, leaving these therapies costly, difficult to produce at scale, and subject to inherent batch-to-batch variability. In this webinar, Dr. Weiheng Su describes how rethinking AAV manufacture “from the ground up” allowed …Read More >

Resource Type: Webinar
Resource Topic: Clinical & Commercial Manufacturing

VIEW